Call Options

12 transactions
Quarter Operation Price Per call calls change calls Held SEC Form
Q3 2024

Nov 14, 2024

SELL
$1.23 - $2.25 $13,284 - $24,300
-10,800 Reduced 22.36%
37,500 $70,000
Q2 2024

Aug 15, 2024

BUY
$2.0 - $4.45 $1,800 - $4,005
900 Added 1.9%
48,300 $97,000
Q1 2024

May 07, 2024

BUY
$2.16 - $5.94 $2,160 - $5,940
1,000 Added 2.16%
47,400 $212,000
Q4 2023

Feb 14, 2024

SELL
$1.11 - $2.34 $96,681 - $203,814
-87,100 Reduced 65.24%
46,400 $107,000
Q3 2023

Nov 14, 2023

SELL
$1.06 - $3.91 $674,690 - $2.49 Million
-636,500 Reduced 82.66%
133,500 $169,000
Q2 2023

Aug 11, 2023

BUY
$3.08 - $9.55 $1.91 Million - $5.92 Million
620,400 Added 414.71%
770,000 $2.53 Million
Q1 2023

May 16, 2023

BUY
$4.0 - $7.02 $598,400 - $1.05 Million
149,600 New
149,600 $614,000
Q3 2021

Nov 15, 2021

SELL
$8.56 - $14.47 $893,664 - $1.51 Million
-104,400 Reduced 81.31%
24,000 $226,000
Q1 2021

May 17, 2021

BUY
$15.31 - $26.52 $1.65 Million - $2.86 Million
108,000 Added 529.41%
128,400 $2.08 Million
Q4 2020

Feb 16, 2021

SELL
$16.84 - $27.59 $166,716 - $273,141
-9,900 Reduced 32.67%
20,400 $543,000
Q3 2020

Nov 16, 2020

BUY
$16.2 - $25.7 $301,320 - $478,020
18,600 Added 158.97%
30,300 $564,000
Q2 2020

Aug 14, 2020

BUY
$5.24 - $23.4 $61,308 - $273,780
11,700 New
11,700 $274,000

Others Institutions Holding MRSN

About Mersana Therapeutics, Inc.


  • Ticker MRSN
  • Exchange NASDAQ
  • Sector Healthcare
  • Industry Biotechnology
  • Shares Outstandng 97,169,296
  • Market Cap $215M
  • Description
  • Mersana Therapeutics, Inc., a clinical stage biopharmaceutical company, develops antibody drug conjugates (ADC) for cancer patients with unmet need. It develops XMT-1592, a Dolasynthen ADC targeting NaPi2b-expressing tumor cells, which is in phase I clinical trial for the treatment of ovarian cancer and NSCLC adenocarcinoma. The company also dev...
More about MRSN
Track This Portfolio

Track Susquehanna International Group, LLP Portfolio

Follow Susquehanna International Group, LLP and customize your updates to receive the information that matters most to you.

Portfolio Update

Get notified when there are updates to the investment portfolio of Susquehanna International Group, LLP, based on Form 13F filings with the SEC.

News

Stay updated on Susquehanna International Group, LLP with notifications on news.